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II instrument in relation to 6 domains proposed. Literature review of diagnosis 
criteria and when to start antiretroviral therapy according to recommended 
guidelines in people living with HIV, following search criteria in the WHO docu-
ment. RESULTS: We established methodological deficiencies in domains 3, 5 
and 6 of AGREE II in the guideline quality assessment. On Domain 3 “Rigour of 
Development” , despite the systematic literature review and quality assessment 
of the evidence reported, recommendations are based on low and very low qual-
ity information, according to GRADE. It means that the recommendations could 
have a high level of uncertainty in the estimation of long term toxicity of first line 
regimes as well as when to start therapy. In Domain 5 “Applicability” we found a 
limitation since the local context on availability of resources, the cost of products 
and other restrictions were practically ignored. States should be obliged to conduct 
this analysis before local adoption with implications of transferability and perti-
nence. Last, in Domain 6 “Editorial Independence” we found the most worrisome 
issue. The 41% of Guideline Development Group members and 25% peer review-
ers disclaimed membership of pharmaceutical industry or other advisory pan-
els, have receipt consulting fees or declared financial support through grants for 
research. Nevertheless, WHO considered this conflict of interest not relevant which 
decrease transparency and credibility of recommendations. CONCLUSIONS: 
Guidelines from WHO constituted an important global reference, however the 
way that HIV guidelines were developed showed worrisome deficiencies in qual-
ity, transparency and transferability. Since the independence of WHO is a matter 
of global controversy, countries must conduct a revision before the adoption of 
guidelines.
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OBJECTIVES: To describe the occurrence rates and causality evidence of cancer 
medication–associated adverse drug reactions (ADRs) and to evaluate Medication 
Utilization in managing the occurred ADRs. METHODS: The patient’s data was 
collected using patient data collection forms in inpatient Radiotherapy depart-
ment. The ADR assessment is done by using WHO causality assessment scale and 
Naranjo’s causality assessment scale. RESULTS: In a total of 536 patients, 78% 
(n= 418) experienced adverse drug reactions. Patients with single adverse drug 
reaction are 43% (n= 178) of 418, whereas 23% (n= 96) experienced two adverse drug 
reactions and 9% (n= 38) were found to be experiencing more than 2 adverse drug 
reactions. Alopecia 95% (n= 397), Nausea and vomiting 82% (n= 343), myelosuppres-
sion 42.1% (n= 176), Skin pigmentation 15.3% (n= 64), itching 11.4% (n= 48), Diarrhea 
11% (n= 46), mucositis 10.2% (n= 43), Constipation 6.22% (n= 26), cardiotoxicity 2% 
(n= 8) are most commonly observed ADRs. The drugs and their proportions for man-
agement of chemotherapy induced adverse drug reactions include Filgrastim (100%), 
metachlopromide (87.0%), different antibiotics like Piperacillin+Tazobactum (77.8%), 
Ceftriaxone (73.3%), Ondansetron (70%) and Dulcolax (66.6%). CONCLUSIONS: 
Approximately 78% of patients taking chemotherapy experienced adverse drug 
reactions that are mostly managed by utilizing proper medications, which further 
elucidate the opportunity for clinical pharmacists to monitor and manage adverse 
drug reactions cautiously, thereby minimizing the after effects of chemotherapy 
and improving the patient’s outcomes.
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OBJECTIVES: Active Surveillance (AS) pharmacovigilance systems better estimate 
the burden of adverse events (AEs) and generate information to allow for more 
efficient use of medicines. The objective of this activity was to implement an AS 
pilot program for first-line antiretroviral therapy (ART) medicines at 2 sentinel sites 
in Namibia. METHODS: The sentinel sites were Windhoek Central Hospital and 
Katutura Intermediate Hospital. Adults naïve to ART were enrolled, an AS Data 
Collection Form was developed and placed into the patient chart, and the doctor 
recorded ART and health information including actively recorded the presence or 
absence of AEs during each follow-up visit. We evaluated data quality by comparing 
data collected through AS forms to medical charts. We assessed incidence of AEs 
using a Cox proportional hazard model. RESULTS: A total of 413 eligible patients 
were included from August 2012 to April 2013. Demographic variables were com-
pleted on average 30% of the time and follow-up visits recorded for 82% of patients. 
Average age was 37 years; WHO Clinical Stage I for 51%; mean baseline CD4 count 
216. Most common ART regimen was TDF/3TC/NVP. The incidence of experiencing 
at least one AE was 0.3/100 person-years. Most common AE was rash followed by 
abdominal pain. After adjustment for age, gender, WHO stage, and CD4 count, those 
on TDF/3TC/EFV had 17.6 times higher risk of experiencing at least one AE (p= 0.002, 
95% CI 2.8-111.8) compared to those on TDF/3TC/NVP, and those with WHO Stage 
2 had 8.8 times higher risk (p= 0.01, 95% CI 1.9-41.2) compared to those with WHO 
Stage 1 disease. CONCLUSIONS: ART regimen and WHO stage influence the risk 
of AEs in Namibia. The quality of data collected through active surveillance in a 
resource-limited setting was high. An economic evaluation is being undertaken to 
evaluate overall feasibility of scale-up of the AS system.
Italy, and Spain, respectively. Empiric treatment with MRSA-active agents was less 
common, with teicoplanin (7.8% in Italy), clindamycin (5.9% in Spain) and van-
comycin (5.8% in Spain) among the most commonly used agents. 38.5%, 71.0%, 
48.0%, and 52.3% of patients were discharged onto continued treatment in Germany, 
UK, Italy, and Spain, respectively. Treatment switching was frequent across coun-
tries. CONCLUSIONS: Treatment of SSTIs is heterogeneous across European coun-
tries; further research is needed to understand the association between empiric 
treatment, treatment switching, and patient outcomes. This analysis, however, 
highlights the potential need for reassessment of treatment guidelines for SSTI 
and the potential need for new SSTI treatments.
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OBJECTIVES: Once-daily STRs have become an increasingly popular choice for both 
newly initiating and treatment experienced patients to improve patient adherence 
and achieve optimal outcomes. This study examines how STR prescribing trends 
have evolved in key EU countries (France, Germany, Italy, Spain and the UK) and pro-
vides insight into physician motivation to switch from conventional anti-retroviral 
(ARVs) regimen dosing to STRs. METHODS: Multi-wave retrospective medical chart 
reviews of HIV patients have been conducted in big-5-EU since 2005 to study patients 
initiating or switching ARVs during each quarter (Q) of the year. Physicians were 
recruited from a large panel to be geographically representative; they abstracted 
patient demographic, disease, and treatment data for next few consecutive HIV 
patients they encountered within a defined time period. This analysis focuses on 
STR prescribing trends between 1Q2009 and 4Q2014. RESULTS: Over 200 physicians 
abstracted 3132 and 3045 patient charts in 1Q2009 and 4Q2014 respectively. STR use 
increased in EU from 17% (France:0.5%, Germany:12%, Italy:16%, Spain:29%, UK:29%) 
in 1Q2009 to 51% in 4Q2014 (France:50%, Germany:67%, Italy:41%, Spain:51%, 
UK:46%). The top reason for switching from conventional ARV dosing to an STR 
across big-5 EU in 1Q2009 was simplification (72%), followed by tolerability (14%), 
and patient decision (12%). Importance of tolerability (19%) increased over the past 
5 years in the decision to switch, while simplification (64%) decreased; patient deci-
sion increased slightly (18%). CONCLUSIONS: STR adoption in the big-5 EU countries 
studied increased rapidly, with Germany and France having the largest increases 
from 1Q2009 to 4Q2014. There was a marked change in impetus to switch to STRs 
from simplification alone to an increasing focus on tolerability. These observed 
trends may emphasize the importance HIV providers give towards maintaining HIV 
patients on a simple and yet tolerable regimen to achieve optimal adherence and 
clinical outcomes over the longer term.
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OBJECTIVES: Acute bacterial skin and skin structure infections (ABSSSI) are among 
the most common infections treated in the hospital setting, and analysis of hos-
pital claims indicate that approximately 74% of ABSSSI hospitalizations involve 
empiric treatment with methicillin-resistant Staphylococcus aureus(MRSA)-active 
antibiotics. Many patients continue treatment post-hospital discharge; little is 
known, however, about real-world prescribing patterns. The purpose of this 
analysis was to characterize current prescribing patterns at hospital discharge 
in the United States (US). METHODS: A retrospective analysis was conducted 
using Arlington Medical Resources’ (AMR’s) Hospital Antibiotic Market audit, 
January-June 2011. The audit is comprised of data elements including patient 
demographics, diagnosis, therapy sequence, switching, and concomitance, hos-
pital and intensive care unit (ICU) length of stay (LOS), discharge drug, and drug 
costs. RESULTS: A sample of 781,331 adult hospitalized patients with ABSSSI who 
received MRSA-active IV antibiotics, projected to national volume, were included 
for analysis. Vancomycin was the most commonly prescribed MRSA-active anti-
biotic, administered to 57.07% of patients at any time during hospitalization. 
Linezolid IV (3.84%), tigecycline (2.88%), and daptomycin (1.92%) were used less 
frequently. Approximately 31% of patients were discharged with an order for 
MRSA-active IV antibiotics. Vancomycin was the most commonly prescribed IV 
antibiotic at discharge, prescribed to 24.83% of patients. Daptomycin was the next 
most commonly prescribed IV drug at discharge (3.71%). All other IV antibiotics 
were prescribed in < 1% of patients. Many patients were prescribed oral antibiot-
ics at discharge, and may have been prescribed more than one drug. Cephalexin 
(33.99%), TMP-SMZ (17.22%), clindamycin (11.08%), and linezolid (9.45%) were the 
most commonly prescribed oral antibiotics at hospital discharge. CONCLUSIONS: 
Approximately 40% of ABSSSI patients are discharged on a MRSA-active antibiotic. 
MRSA-active antibiotics that do not require multiple days of ambulatory treat-
ment following hospitalization have the potential to reduce resource utilization 
associated with continued outpatient treatment.
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OBJECTIVES: To conduct an assessment of the quality of “Consolidated guide-
lines on the use of antiretroviral drugs for treating and preventing HIV infec-
tion. Recommendations for a public health approach June 2013” by World Health 
Organization (WHO). METHODS: Quality assessment of guideline using AGREE 
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with lower and Hispanic ethnicity with higher ALD rate only among the disabled 
born 1945-65 but not other cohorts. CONCLUSIONS: ALD prevalence patterns were 
complex and were modified by race, elderly/disability status, and the extent of 
health care access and screening capacity in the county of residence. These study 
results help inform treatment strategies for HCV in the context of coordinated 
models of care.
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OBJECTIVES: This study aimed to examine whether phototherapy (ultraviolet light 
B) can lower the risk of fractures in vitiligo patients over middle age. METHODS: 
Using the 2000-2010 Taiwan’s National Health Insurance research database, we 
identified patients with newly diagnosed vitiligo between 2003 and 2009 at age 40 
years or older. Following the diagnosis, the patients were entered into three cohorts, 
based on the frequency of phototherapy they received. The patients who received 
phototherapy equal or more than 12 times yearly were grouped into “frequent 
phototherapy cohort”; those who received phototherapy between 1 and 12 times 
yearly, “infrequent phototherapy cohort”; those who received no phototherapy, 
“phototherapy unreceived cohort”. The patients were followed until the first hip or 
vertebral fracture, death, or 31 December 2010. Cox regression models were used 
for analysis. Further analyses stratified by age and sex were carried out. RESULTS: 
We identified 3,863 patients with newly-onset vitiligo over middle age (mean age: 
57). Among these patients, 747 (19.3%) received phototherapy equal or more than 
12 times yearly, 712 (18.4%) received phototherapy between 1 and 12 times yearly, 
and 2,404 (62.2%) received no phototherapy. The frequent phototherapy cohort had 
an insignificant lower risk of fracture than the phototherapy unreceived cohort 
(adjusted hazard ratio (aHR) = 0.57, 95%CI = 0.29-1.10, p = 0.095), while the infre-
quent phototherapy cohort had a similar risk of fracture compared with the photo-
therapy unreceived cohort (aHR = 0.91, 95%CI = 0.51-1.61, p = 0.738). The stratified 
analyses showed that the patients aged 40~64 years in the frequent phototherapy 
cohort had a lower risk of fracture than those in the phototherapy unreceived cohort 
(aHR = 0.28, 95%CI = 0.10-0.79, p = 0.016). CONCLUSIONS: This study suggested 
that a frequent use of phototherapy might reduce the fracture risks among vitiligo 
patients at middle-age.
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OBJECTIVES: Remote monitoring strategies (RM) have the potential to deliver spe-
cialised care and management to patients with stable heart failure (HF). This review 
sought to determine whether RM improves outcomes for adults with stable HF 
(defined as having no acute event or deterioration in the past 28 days) who are man-
aged in the community (ambulatory or outpatient care setting). METHODS: Fourteen 
electronic databases covering the biomedical, scientific and grey literature were 
searched to November 2013, and supplemented by hand-searching relevant articles. 
Two reviewers independently extracted all relevant data. All randomised controlled 
trials (RCTs) were included. RM interventions included home telemonitoring (TM) 
with medical support provided during office hours or 24/7 and structured telephone 
support (STS) programmes delivered via human-to-human contact (HH) or human-to-
machine (voice-activated) interface (HM). RESULTS: Eighteen RCTs were included in 
the systematic review. Compared with usual care, the network meta-analysis showed 
that RM was beneficial in reducing all-cause mortality for STS HH (Hazard Ratio, HR: 
0.87, 95% Credible Interval, CrI: 0.66, 1.15), TM during office hours (HR: 0.81, 95% CrI: 
0.57, 1.16) and TM 24/7 (HR: 0.85, 95% CrI: 0.57, 1.26); however, these were statistically 
inconclusive. No favourable effect on mortality was observed with STS HM. Similarly, 
trends in reducing HF-related hospitalisations were also observed for all RM interven-
tions. CONCLUSIONS: STS HH and TM with medical support provided during office 
hours or 24/7 showed beneficial trends, particularly in reducing all-cause mortality 
for patients with stable HF. However, due to the complex nature of RM interven-
tions (including between study heterogeneity within each category), further research 
should seek to examine the ‘active ingredients’ of RM strategies including suitability 
of different systems and qualitative research (patient, partners or carers’ experiences) 
to understand the processes by which RM works.
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OBJECTIVES: The WHO has been proposing and updating a working definition of 
dengue since 1974. This definition can aid clinical prediction of severe outcomes 
and triage. Dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS) 
were defined in a 1997 report. Several issues were identified with the 1997 clas-
sification, as the need for a new definition that adequately and earlier the clinical 
spectrum of the disease. In 2009, WHO release a new classification. The objective 
was to assess 1997 and 2009 WHO classifications of severe dengue. METHODS: 
A retrospective cohort study was carried out in a pediatric university hospital in 
Cartagena, Colombia. Consecutive patients admitted to the emergency department 
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OBJECTIVES: To characterize the frequency, cost, and hospital-reported out-
comes of cachexia and debility in children with complex chronic conditions 
(CCCC). METHODS: We analyzed data from the 2003-2012 data releases of the Kids’ 
Inpatient Database (Healthcare Cost & Utilization Project, Agency for Healthcare 
Research & Quality), utilizing International Classification of Diseases, 9th Revision 
(ICD-9) diagnosis codes to identify cases. We compared patient and hospitaliza-
tion characteristics for CCCC with and without cachexia (ICD-9 799.4) and debility 
(ICD-9 799.3). We examined factors which predict odds of inpatient mortality in 
CCCC using a logistic regression model and factors which impact length of stay and 
cost in CCCC using negative binomial regression models. All costs are reported in 
2014 dollars, using the Consumer Price Index inflation adjustment. RESULTS: We 
estimated hospitalization incidence of cachexia in CCCC at 1,395 discharges during 
the sample period, which increased from 277 discharges in 2003 to 473 discharges in 
2012, 421 discharges which included debility, which increased from 39 discharges in 
2003 to 217 discharges in 2012. During the sample period, 5.73% and 2.44% of CCCC 
with cachexia and debility, respectively, died during their hospital stay. Cachexia 
was associated with a 59% increase in odds of inpatient mortality while debil-
ity was associated with a 41% decrease in odds of mortality. Both cachexia and 
debility increased hospital length of stay (15% and 31% longer stays, respectively). 
The median cost of hospitalization was $15,441.59 and $23,796.16 for children with 
cachexia and debility, respectively. CONCLUSIONS: The frequency of hospitaliza-
tion for cachexia in CCCC is less than that for adults; however, the frequencies of 
cachexia diagnoses are increasing over time. Estimates of the incidence of hospitali-
zation with debility in CCCC have not been previously reported in the literature, but 
our study demonstrates that the frequency of these discharges is also increasing.
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OBJECTIVES: To identify patient-level and hospital-level factors associated with 
inpatient mortality in a cohort of ischemic stroke patients. METHODS: The 2012 U.S. 
Nationwide Inpatient Sample was used to identify patients with a primary diagnosis 
for ischemic stroke (ICD-9: 433,434,436) in the South Region. Backward selection 
technique with logistic regression was performed to identify unique patient-level 
and hospital-level factors associated with inpatient mortality. The multivariable 
analysis included hospitals with more than 30 stroke cases in the southern region 
of the U.S. RESULTS: There were 19,071 hospitalizations for stroke in 320 hospitals 
in the South Region. The patient-level variables associated with an increased risk 
of inpatient mortality were age> 65, female gender, being white, expected primary 
payer Medicaid, private or other, score for risk of mortality, number of procedures, 
and having comorbidity of paralysis. On the other hand, number of chronic condi-
tions, having major operating room procedure, AIDS, anemia, chronic pulmonary 
disease, diabetes with chronic complications, peripheral vascular disorder, or val-
vular disease were found to be associated with lower risk of mortality. Additionally, 
interaction terms involving age, number of procedures, race, risk of mortality score 
and expected payer were found to be significant predictors. As for hospital-level 
risk factor, urban-teaching [OR= 0.51(p= 0.001)] and urban-non-teaching [OR= 0.52 
(p= 0.003)] hospitals were associated with lower mortality risk as compared to any 
rural hospitals. CONCLUSIONS: Both patient-level and hospital level factors play an 
important role in influencing in-hospital mortality of stroke patients thus under-
scoring the need to better understand the causes of death after stroke in order to 
develop strategies to improve outcomes. Close examination of reasons for relatively 
poor performance of rural hospitals in inpatient mortality of stroke patients requires 
future studies.
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OBJECTIVES: We examined patient and county-level characteristics associated 
with advanced liver disease (ALD) at hepatitis C (HCV) diagnosis in three Medicare 
cohorts: 1) elderly born before 1945; 2) disabled born 1945-1965; 3) disabled born after 
1965. METHODS: Data source was Medicare claims (2006-2009) linked to the Area 
Health Resource Files. ALD was measured over the period of 6 months before to 3 
months after diagnosis. Using weighted multivariate modified Poisson regressions 
to address generalizability of findings to all Medicare HCV patients, we modelled 
the association between contextual characteristics and the presence of ALD at HCV 
diagnosis. RESULTS: We identified 1746, 3351, 592 patients with ALD rates of 28.0%, 
23.0%, and 15.0% for birth cohorts 1), 2), 3). The prevalence of drug abuse increased 
among younger birth cohorts: 4.2%, 22.6%, and 35.6%, respectively. HIV co-infection 
(RR= 0.63, p= 0.001), dual Medicare/Medicaid eligibility (RR= 0.89, p= 0.017), residence 
in counties with higher median household income (RR range 0.82-0.86, p= 0.009-
0.065), higher density of primary care providers (RR range 0.84-0.86, p= 0.022-0.041), 
and more rural health clinics (RR= 0.90, p= 0.084) were associated with lower ALD 
rates. End stage renal disease (RR= 1.41, p= 0.001), alcohol abuse (RR= 2.57, p= 0.001), 
hepatitis B co-infection (RR= 1.32, p= 0.004), and residence in the Midwest (RR= 1.22, 
p= 0.010) were associated with higher ALD rates. Living in rural counties with high 
screening capacity was protective in the elderly but associated with higher ALD rates 
among the disabled born 1945-65. Compared to Whites, Black race was associated 
